Elanco’s first quarter results were met with a positive market reaction, as management pointed to broad-based revenue growth across its pet health and farm animal businesses. CEO Jeffrey Simmons credited the performance to momentum from newly launched products—especially Zenrelia and Credelio Quattro—and share gains in major U.S. and international categories. The company’s execution on its innovation strategy, combined with increased presence at key retail partners, underpinned Elanco’s ability to outperform Wall Street’s revenue and profit expectations. Simmons highlighted, “Our momentum in each of our 4 businesses is evident in market share gains across our global portfolio.”
Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).
Elanco (ELAN) Q1 CY2026 Highlights:
- Revenue: $1.37 billion vs analyst estimates of $1.28 billion (14.9% year-on-year growth, 6.8% beat)
- Adjusted EPS: $0.40 vs analyst estimates of $0.34 (16.6% beat)
- Adjusted EBITDA: $334 million vs analyst estimates of $300.1 million (24.4% margin, 11.3% beat)
- The company lifted its revenue guidance for the full year to $5.05 billion at the midpoint from $4.99 billion, a 1.3% increase
- Management raised its full-year Adjusted EPS guidance to $1.06 at the midpoint, a 2.9% increase
- EBITDA guidance for the full year is $990 million at the midpoint, above analyst estimates of $978 million
- Operating Margin: 11.2%, up from 9.4% in the same quarter last year
- Constant Currency Revenue rose 10% year on year (4% in the same quarter last year)
- Market Capitalization: $10.7 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Elanco’s Q1 Earnings Call
- Jonathan Block (Stifel) asked about the factors influencing the acceleration in U.S. Pet Health growth, especially after a softer start to the quarter. CEO Jeffrey Simmons explained that March and April saw a sharp rebound, driven by Zenrelia, Credelio Quattro, and new retail partnerships.
- Michael Ryskin (Bank of America) focused on Zenrelia’s performance despite U.S. label restrictions and the path toward further label improvements. Simmons described Zenrelia’s efficacy as the key driver and noted that additional data requested by the FDA is being collected, with further upside possible if label updates are approved.
- Umer Raffat (Evercore) inquired about the sustainability of farm animal growth, particularly in cattle and poultry. Simmons cited strong protein consumption trends and Elanco’s market position, expecting these drivers to persist even as herd sizes fluctuate.
- Brandon Vazquez (William Blair) sought clarification on the ramp dynamics in U.S. Pet Health, especially regarding the progression of new product penetration. CFO Bob VanHimbergen pointed to ongoing momentum in clinics, increased DTC investment, and growing corporate account contracts as supporting further acceleration.
- Daniel Clark (Leerink) questioned the international share gains for Zenrelia and competitive intensity in the dermatology market. Simmons highlighted double-digit international derm market growth and strong acceptance of Zenrelia, underscoring its rapid market share gains in countries like Brazil and Japan.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be tracking (1) the pace of Zenrelia and Befrena adoption in both U.S. and international veterinary clinics, (2) gross margin improvements driven by the Elanco Ascend productivity program, and (3) the effectiveness of new retail partnerships such as Costco and Dollar General in sustaining OTC growth. Progress on further regulatory approvals and successful global expansion of the innovation portfolio will also be important performance indicators.
Elanco currently trades at $21.38, down from $22.99 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
